Arcturus Therapeutics Holdings (ARCT) Cash & Equivalents (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Cash & Equivalents data on file, last reported at $211.4 million in Q1 2026.

• Quarterly Cash & Equivalents fell 2.57% year-over-year to $211.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $211.4 million (down 2.57% YoY) and the FY2025 annual result came in at $230.9 million, down 21.44% from the prior year.
• Cash & Equivalents eased to $211.4 million in Q1 2026, from $230.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $391.9 million in Q4 2022 to a low of $180.4 million in Q3 2025.
• A 5-year average of $270.8 million and a median of $283.5 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 42.57% — and 2023, when it surged 31.24%.
• Tracing ARCT's Cash & Equivalents over 5 years: stood at $391.9 million in 2022, then declined by 25.49% to $292.0 million in 2023, then gained by 0.65% to $293.9 million in 2024, then fell by 21.44% to $230.9 million in 2025, then declined by 8.46% to $211.4 million in 2026.
• The last three Cash & Equivalents figures came in at $211.4 million (Q1 2026), $230.9 million (Q4 2025), and $180.4 million (Q3 2025), per Business Quant data.